Journal of Thoracic Oncology:
doi: 10.1097/01.JTO.0000445597.81357.1b
Submitted Abstracts

Subject Index

Free Access
Back to Top | Article Outline


A protease inhibitor of CD13, S31

A549 cell line, S12, S13

Accelerated hyperfractionation, S36

Adenocarcinoma, S8

Adherence, S43

Adjuvant chemotherapy, S31, S32

Adjuvant immunotherapy, S31

Adriamycin, S29

Advanced non small cell lung cancer, S47

Afatinib, S41

Akt, S12

ALK gene, S7

anaplastic lymphoma kinase (ALK) S9, S33

Awareness program, S18

Back to Top | Article Outline


BCL3, S23

Benign lesions, S9

Benzo (a) pyrene, S13

Beta-glucan, S40

Bevacizumab, S29, S47, S49

Biomarkers, S24

Bone marker, S50

Bone metastases, S50

Bone morphogentic protein, S8

BRAF mutation, S30

Brain Metastases, S36, S46

Bronchoscopy, S27

Back to Top | Article Outline


Cabazitaxel, S28

Cabozantinib, S38

Cancer, S17

Cancer registries, S14

Cancer stem cell, S33

Cancer vaccine, S23

Cancer-related anemia, S48


CD133, S33

CD47, S30

Cell culture, S8

cell-free DNA, S9

Cetuximab, S40

Chemo resistant, S29

Chemoradiation, S33

Chemo-radiotherapy, S35, S36

Chemoresitance, S21

Chemotherapy, S42

Chemotherapy-induced anemia, S48

Chest X-ray, S17

Chromosome 7 high polysomy, S44

Cigarette smoking, S11

Circulating tumor cells, S19

Cisplatin, S9, S47

c-MET gene, S7

CO-1686, S38

Comorbidity, S43

Companion diagnostic, S26

Companion imaging agent, S23

Comparative effectiveness research, S31

Comprehensive Histologic Assessment, S7

Computed tomography S14, S27

Cost-effectiveness, S16

CT imaging, S27

CT-guided biopsy, S27

ctr1, S22

Curcumin, S22

Customized therapy, S36

Cyclooxygenase 2 (COX-2), S11

Cyclophosphamide, S29

Cytolysin, S12

Back to Top | Article Outline


Darbepoetin alfa, S48

Death-associated protein kinase (DAPK), S24

Disease progression, S28

Dose adjustment, S31

DOX, S13

Drug screening, S21

Back to Top | Article Outline


Early detection, S15, S16

Early diagnosis, S15

Early stage disease, S15, S31


EGFR inhibitor, S22

EGFR mutation, S9, S10, S16, S19, S27, S36, S37, S40, S44, S45

EGFR tyrosine kinase inhibitor, S19

EGFR-TKI, S9, S38, S44

Elderly, S35, S43

Endobronchial ultrasound, S26, S27

Endobronchial ultrasound guided transbronchial needle aspiration, S27

Epidemiology, S14

Epidermal growth factor receptor (EGFR), S10

Epigallocatechin gallate (EGCG), S47


Erlotinib, S37, S41

Erythropoiesis-stimulating agent, S48

Estrogen receptor beta, S8

Etarfolatide (EC20), S26

Ethnicity, S21

Evaluation, S18

Exon 20 insertion, S40

Extensive-stage SCLC, S20

Extrapleural pneumonectomy, S50

EZH-2, S11

Back to Top | Article Outline


18F-FDG PET/CT, S25, S51


First-line chemotherapy, S43

Fluorescent in situ hybridization (FISH), S7, S38

Folate, S26

Folate Receptor, S22

Free-circulating DNA, S19

Gefitinib, S38, S42

Back to Top | Article Outline


γ-Fe2O3-NC, S13

Gemcitabine, S20, S46

Gene E, S24

Gene expression analysis, S10

Gene expression signatures, S32

Gene rearrangement, S9, S33

Gene therapy, S25

Genetic alterations, S7

Genome wide association study, S32

Genomic profile, S38

Germ cell tumor, S52


Back to Top | Article Outline


Hedgehog, S51

High hydrostatic pressure, S23

Histology, S8

Hsp90, S19, S23

Back to Top | Article Outline


Imaging, S52

Immunohistochemistry, S7, S9, S23, S33

Immunotherapy, S25, S39, S41

Incidence, S17

Induction treatment, S35

Inhibitor of apoptosis protein, S21

Intensity modulated radiation therapy (IMRT), S35, S49

Interleukin-2, S47

Intermittent therapy, S40

International, S17

Intrapleural hyperthermic chemotherapy, S47

Intrapleural treatment, S51

Irreversible EGFR-TKI, S38

Back to Top | Article Outline



Lepidic growth, S7, S10

Local ablation techniques, S25

Local tumor control, S34

Locally advanced disease, S35, S36

Locally advanced non-small cell, S35

Long non codingRNA, S51

LUME Lung 1, S39

Lung adenocarcinoma, S32, S44

Lung biopsy, S27

Lung cancer recurrence, S27

Lung cancer screening, S14, S17

Lung cancer, S7, S12, S13, S15, S16, S17, S18, S24, S27, S32, S42

Lung flooding, S25

Lung screening, S15

Back to Top | Article Outline


Macrophage, S30

Maintenance chemotherapy, S46

Malignant mesothelioma, S50, S51

Malignant pleural dissemination, S47

Malignant pleural effusion, S47

Malignant pleural mesothelioma, S14, S51

Mediastinal invasion, S34

Mediastinal tumor, S52

Mesothelioma, S50, S51

MET, S19

Meta-analysis, S42

Metabolic profile, S13

microRNA (miRNA), S14, S16, S20, S22, S50

Microsatellite marker, S13

Mixed pathology tumour, S30

Molecular biomarkers, S30

Morphogenetics, S12

Morphology S27

Mouse model, S13

mTOR pathway, S11

mTOR, S10

Mucin 1, S25

Multifocal lung adenocarcinoma, S7

Napsin A, S10

Back to Top | Article Outline


Neoadjuvant therapy, S36

New targeted therapies, S30

Nintedanib, S39, S41

Non-small cell lung cancer (NSCLC), S9, S11,S12, S14, S16, S18, S19, S20, S22, S23, S24, S25, S26,S32, S33, S34, S35, S36, S37, S38, S39, S40, S41, S42, S43, S44, S45, S46, S47, S48, S48, S49, S50

Nuclear target, S13

Back to Top | Article Outline


Oligometastatic disease, S42, S49

Outcome prediction, S20

Outcomes, S27

Overall survival (OS), S29, S33

Back to Top | Article Outline


p53, S11, S13

Paclitaxel, S25, S29

Palliative radiotherapy, S45

Pathological stage I, S31

Pathology, S52

Patient selection, S23

PD-1, S18

PD-L1, S18

Pemetrexed, S19, S41, S45, S46

Phase III, S39

Plasma Biomarkers, S9, S25

Platinum resistance, S21

Polymorphisms, S16, S32

Population-based study, S15

Post-operative radiotherapy, S34

Post-operative, S36

Predictive biomarker, S12, S41

Predictive factor, S19

Predictor, S31

Previously treated, S47

Prognosis S10, S16, S32, S38

Prognostic factors, S52

Prognostic marker, S8

Prognostic signature, S50

Programmed death-1 ligand, S41

Programmed death-1 receptor, S39

Progression-free survival (PFS), S24

Prolonged low-dose infusion, S46

Proteasome, S23

PS2, S42

PTK7, S12

Pulmonary neuroendocrine tumors, S10

Back to Top | Article Outline


Quality assurance, S26

Quality of life (QOL), S37

Quantitative real-time polymerase chain reaction (Q-RT-PCR), S16

Quiescence, S51

Back to Top | Article Outline


Radiation therapy, S21, S33, S35

Rash, S41

Rechallenge chemotherapy, S28

Recurrence, S8, S51

Response, S35

Response to TKIs, S40

RET, S38

Retrospective study, S34, S46

Risk, S17


rs8100239, S23

Back to Top | Article Outline


Safe practices, S18

Safety, S49

Sarcomatoid, S7


Sea anemone venoms, S12

Second-line chemotherapy S28, S29

Smac mimetics, S21

Small cell lung cancer (SCLC), S28, S29, S30

SNP, S23

Solitary fibrous tumor of the pleura, S52

Solitary nodule, S31

Somatic profiling, S19

South India, S18

Spore-forming bacillus S11

Squamous cell carcinoma, S16, S31, S40

Src, S22

Stage I lung adenocarcinoma, S10

Staging, S26

Standard dose, S46

Stereotactic radiotherapy, S15, S31

Study 20070782, S48

Subtyping lung adenocarcinomas, S12

Surgery, S34, S42

Survival, S8, S34, S35

Survival analysis, S14

Back to Top | Article Outline


T790M mutation, S38

Targeted therapy, S22

Telomerase activity, S24

Telomere length, S24

Temozolomide, S46

TGF-bR signaling, S24

Therapeutic insufficiency, S29

Therapeutic regiments, S29

Therapeutic ultrasound, S25

Thymidylate synthase (TS), S41

Thyroid cancer, S27

TKI, S37, S40

Tobacco cessation, S18

Tobacco, S17

Topotecan, S28, S29

Transcriptomics, S20

Transporter, S21

Treatment, S43, S52

Tumor biology, S8

Tumor biomarker, S16

Tumor specific antibodies S11

Tumor volume, S37

Tyrosine kinase inhibitor (TKI), S44

Back to Top | Article Outline


Vincristine, S29

Back to Top | Article Outline


Whole-brain radiation therapy, S49

Back to Top | Article Outline


Xiap, S22

Back to Top | Article Outline


Young adults, S48

Copyright © 2014 by the European Lung Cancer Conference and the International Association for the Study of Lung Cancer.


Article Tools


Other Ways to Connect



Visit on your smartphone. Scan this code (QR reader app required) with your phone and be taken directly to the site.

 For additional oncology content, visit LWW Oncology Journals on Facebook.